Sun receives FDA approval for carboplatin injections
This article was originally published in Scrip
Sun Pharmaceutical Industrieshas received US FDAapproval for its ANDA for carboplatin 10mg/ml injections packed in 5ml, 15ml and 45ml single use vials, generic versions of Bristol Myers Squibb's Paraplatin injections. Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma. These strengths of Paraplatin injections reported annual sales of about $45 million in the US.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?